United Therapeutics Corporation (UTHR)
News
| May 21 | Health Care Sector Wrap Fox Business |
| May 10 | Hedging Biotechs As R&D Investment Declines |
| May 08 | Health Care Sector Wrap Fox Business |
| May 07 | 4 Undervalued Mid-Cap Stocks Bringing In Profits |
| May 03 | $UTHR Mentioned more than normal on StockTwits - Currently at 9 x average daily social activity by TradeIdeasQuant |
| May 03 | I have already accepted my losses for the day...still in half $WFM and half $UTHR. DO NOT FIGHT TO GET BACK YOUR LOSSES EVER. ACCEPT by hedgefundhell |
| May 03 | $UTHR cut in half here 43.94 stop on second half by hedgefundhell |
| May 03 | $UTHR 43.94 stop now by hedgefundhell |
| May 03 | $UTHR Fill...remember watch your stocks, not the market by hedgefundhell |
| May 03 | $WFM Fill $UTHR 44.15 BS by hedgefundhell |
| Apr 27 | Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and U... |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Drug Manufacturers - Other
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company's products include Remodulin, Tyvaso and Adcirc. The company operates through two business segments: Pharmaceuticals and Telemedicine. Its lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. The company was founded by Martine Rothblatt in June 26, 1996 and is headquartered in Silver Spring, Maryland.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). United Therapeutics Corporation is down 32.18% over the last year vs S&P 500 Total Return up 2.03%, Cubist Pharmaceuticals up 4.10%, and Cumberland Pharmaceuticals up 20.83%.
- UTHR Total Returns
- ^SPXTR Total Returns
- CBST Total Returns
- CPIX Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these UTHR related companies
Pro Strategies Featuring UTHR
Did United Therapeutics Corporation make it into our Pro Portfolio Strategies?
UTHR Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other UTHR Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| UTHR | 44.05 | +1.38 | +3.23% | 2.362B |
| USTR | 25.52 | +0.18 | +0.71% | 1.080B |
| USO | 34.22 | -0.04 | -0.12% | |
| USMO | 12.68 | -0.04 | -0.31% | 280.35M |
| USG | 15.67 | -0.18 | -1.14% | 1.651B |
| USD | 33.80 | +0.62 | +1.87% | |
| USBI | 4.76 | -0.16 | -3.25% | 28.66M |
| URS | 36.76 | -0.18 | -0.49% | 2.926B |
| URRE | 0.7301 | +0.01 | +1.33% | 77.43M |
| URG | 0.9217 | +0.01 | +1.29% | 111.47M |
